Uganda Cancer Institute, P. O. Box 3935, Kampala, Uganda.
Department of Medicine, Habib Medical School, Islamic University in Uganda, Kampala, Uganda.
BMC Cancer. 2022 Feb 23;22(1):204. doi: 10.1186/s12885-022-09300-1.
Lung cancer is a leading cause of cancer-related deaths in Uganda. In this study, we aimed to describe the baseline characteristics and survival of patients with lung cancer at the Uganda Cancer Institute (UCI).
We retrospectively reviewed medical records of all patients with a histological diagnosis of lung cancer registered at UCI between January 2008 and August 2018. Data on demographic, clinical, and treatment characteristics, and vital status were abstracted and analyzed. Patients with undocumented vital status on the medical records were contacted through phone calls. We determined survival as time from histological diagnosis to death. The Kaplan-Meier survival analysis was performed to estimate the median survival time and the 5-year overall survival rate.
Of the 207 patients enrolled, 56.5% (n = 117) were female, median age was 60 years (range: 20-94), 78.7% (n = 163) were never-smokers and 18 (8.7%) were living with HIV. Presumptive anti-tuberculosis treatment was given to 23.2% (n = 48). Majority had non-small cell lung cancer (96.6%, n = 200) with 74.5% (n = 149) adenocarcinoma and 19% (n = 38) squamous cell carcinoma. All had advanced (stage III or IV) disease with 96.1% (n = 199) in stage IV. Chemotherapy (44.9%, n = 93) and biological therapy (34.8%, n = 72) were the commonest treatments used. Overall survival at 6 months, 1-, 2- and 5-years was 41.7, 29.7, 11.8, and 1.7%, respectively. The median survival time of 4.4 months was not statistically significantly different between participants with NSCLC or SCLC (4.5 versus 3.9 months, p = .335).
In Uganda, adenocarcinoma is the predominant histologic subtype of lung cancer and patients are predominantly females, and non-smokers. Patients present late with advanced disease and poor overall survival. Public awareness should be heightened to facilitate early detection and improve outcomes.
肺癌是乌干达癌症相关死亡的主要原因。本研究旨在描述乌干达癌症研究所（UCI）肺癌患者的基线特征和生存情况。
我们回顾性分析了 2008 年 1 月至 2018 年 8 月期间在 UCI 登记的所有组织学诊断为肺癌的患者的病历。提取并分析了人口统计学、临床和治疗特征以及生存状态的数据。对于病历上未记录生存状态的患者，我们通过电话进行了联系。我们将生存时间定义为从组织学诊断到死亡的时间。采用 Kaplan-Meier 生存分析估计中位生存时间和 5 年总生存率。
在纳入的 207 名患者中，56.5%（n=117）为女性，中位年龄为 60 岁（范围：20-94 岁），78.7%（n=163）为从不吸烟者，18 人（8.7%）为 HIV 感染者。23.2%（n=48）接受了疑似抗结核治疗。大多数患者患有非小细胞肺癌（96.6%，n=200），其中 74.5%（n=149）为腺癌，19%（n=38）为鳞状细胞癌。所有患者均为晚期（III 或 IV 期）疾病，96.1%（n=199）为 IV 期。化疗（44.9%，n=93）和生物治疗（34.8%，n=72）是最常用的治疗方法。6 个月、1 年、2 年和 5 年的总生存率分别为 41.7%、29.7%、11.8%和 1.7%。非小细胞肺癌和小细胞肺癌患者的中位生存时间分别为 4.4 个月和 3.9 个月，无统计学差异（4.5 与 3.9 个月，p=0.335）。
在乌干达，腺癌是肺癌的主要组织学亚型，患者主要为女性和不吸烟者。患者就诊时已处于晚期，疾病预后较差。应提高公众意识，以促进早期发现和改善预后。
